期刊文献+

多发性骨髓瘤成骨细胞活性和Runx2的表达 被引量:1

Osteoblast activity and Runx2 expression in multiple myeloma
下载PDF
导出
摘要 目的研究多发性骨髓瘤(MM)患者间充质干细胞(MSCs)向成骨细胞(OB)分化过程中Runx2的表达,探讨MM骨形成障碍的机制。方法以4例有明显骨质破坏的MM患者为研究对象,2例缺铁性贫血和1例特发性血小板减少性紫癜为对照,体外诱导MSCs向OB分化,采用CCK-8试剂盒检测MSCs向OB分化过程中的增殖能力,以平均光密度值(AOD)表示;碱性磷酸酶(ALP)染色和钙结节(Von-Kossa)染色检测MSCs的OB形成能力,分别以IOD sum/Area sum值和平均钙结节个数表示;逆转录-聚合酶链反应(RT-PCR)技术检测MSCs向OB分化过程中Runx2的表达,以Runx2/GAPDH平均光密度值表示。结果在MSCs向OB分化过程中,MM患者MSCs的增殖能力、ALP表达、钙结节形成能力、Runx2表达均明显低于对照组(P<0.01)。结论 MM患者骨髓MSCs向OB分化过程中的增殖能力和OB形成能力均下降,可能与Runx2的表达减低有关。 Objective To evaluate Runx2 expression of mesenchymal stem cells(MSCs) from bone marrow of multiple myeloma(MM),and discuss the mechanism of osteoblast inhibit ion in MM.Methods Bone marrow was collected from four MM patients with obvious osteolytic lesion.The control group included two patients with iron deficiency anemia and one with idiopathic thrombocytopenic purpura.MS C s were induced to differentiate into OB in vitro.CCK-8 kit was employed to ana lyze MSCs proliferation,defined as the average optical density(AOD).Alk aline phosphatase staining and Von-Kossa staining were performed to assess oste oblast formation,defined as IOD sum/Area sum and the average of calcium nodules respectively.RT-PCR assays were applied to detect Runx2 expression of MSCs,d e fined as Runx2/GAPDH average optical density.Results The r e was significant difference in the proliferation of MSCs between MM and control group.The osteoblast formation was less in MM group than that of control g roup.RT-PCR assays showed that Runx2 expression was significantly lower in MM than that in control group(all P0.01).Conclusions In the course of differentiation of MSCs into OB,bone marrow MSCs fro m MM patients are characterized with a low proliferation and osteoblast formatio n,which may be associated with lower expression of Runx2.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第22期4366-4368,共3页 Chinese Journal of Gerontology
基金 国家自然科学基金(No.30871111)
关键词 多发性骨髓瘤 间充质干细胞 成骨细胞 Multiple myeloma Mesenchymal stem cells Osteoblasts
  • 相关文献

参考文献1

二级参考文献17

  • 1林如峰,陆化,刘澎,沈文怡,张建富,吴雨洁,费小明,李建勇.蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响[J].中国实验血液学杂志,2006,14(1):61-64. 被引量:7
  • 2Yeh HS,Berenson JR. Myeloma bone disease and treatment options. Eur J Cancer 2006,42:1554-1563.
  • 3Pilarski LM, Hipparson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.Blood 2000,95(3):1056-1065.
  • 4Yaccoby S, Wezeman M J, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004,64(6):2016-2023.
  • 5Okada T,Akikusa S, Okuno H, et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 2003,20(7):639-646.
  • 6Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.Blood 2005,106(9):3160-3165.
  • 7Silvestris F,Cafforio P,Calvani N,et al. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004,126(4):475-486.
  • 8Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004,32(8):685-691.
  • 9Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differention in multiple myloma.Blood 2005,106(4):1407-1414.
  • 10Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003,349(26):2483-2494.

同被引文献21

  • 1Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma [ J ]. Lancet,2009,374 (9686) :324-339.
  • 2Zeng Z, Zhang C, Chen J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts [ J ]. J Bone Miner Metab, 2013,31 ( 4 ) : 409-416.
  • 3Tucci M, Stucci S, Savonarola A, et al. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation[ J]. Br J Haemato1,2013,161 (6) :821-831.
  • 4Champagne E. gammadeha T cell receptor ligands and modes of antigen recognition [ J ]. Arch Immunol Ther Exp (Warsz), 2011, 59(2) :117-137.
  • 5Meraviglia S, Caecamo N, Salerno A, et al. Partial and ineffective activation of Vgamma9Vdeha2 T cells by Mycobacterium tuberculosis-infected dendritic cells [ J ]. J Immunol, 2010, 185 (3) :1770-1776.
  • 6Terpas E, Dimopoulos MA, Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease[ J]. Crit Rev Oncol Hemato1,2011,77 Suppl 1 :S13-S23.
  • 7Roodman GD. Pathogenesis of myeloma bone disease [ J ]. J Cell Biochem,2010,109 (2) :283-291.
  • 8Ciolli S. Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs [ J ]. Clin Cases Miner Bone Metab ,2013,10(3 ) : 183-186.
  • 9Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma [ J ]. J Clin Oncol, 2007,25(17) :2464-2472.
  • 10Terpos E. Bisphosphonate anticaneer activity in multiple myeloma [J]. Anticancer Agents Med Chem,2012,12(2) :123-128.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部